IBSincluding several Jeff Beck patent applications and patents that will

(IBS),including several explains Jeff Beck patent applications jeff beck "love is blue investigates and patents that will expand the Neogenixintellectual property portfolio, and enhance the opportunity for developingadditional therapeutics and diagnostics beyond what is currently in development.Under the terms of the agreement, current IBS shareholders will have theopportunity to become shareholders in Neogenix Additional terms of thetransaction have not been disclosed. The sale of these assets was recentlyapproved by the IBS board and the IBS shareholders. The decision by IBS totransfer its assets to Neogenix is one of several steps IBS is taking as part ofthe planned dissolution of the company. Neogenix CEO and founder, Myron Arlen, MD, commented that with the addition ofthe IBS assets to the Neogenix platform, it could be possible to combinepreviously developed IBS technology with the Neogenix platform ofimmunodiagnostic and therapeutic antibodies and their associated tumorassociated antigens (TAAs) to develop important new products that may provide asignificant benefit to cancer patients Dr.

Arlen`s vision, energy, anddedication played a key role in completing this transaction jeff beck wired . "The acquisition of this intellectual property and associated technologystrengthens our existing platform for developing therapeutics and diagnosticsfocused on pancreatic, colorectal, and other important cancers," said NeogenixPresident and Chief Medical Officer, Philip M Arlen, MD jeef beck . "These patents are animportant addition to our portfolio, and could accelerate our efforts to producemore potent antibodies." About Neogenix Oncology, Inc.Founded in 2004 and headquartered in Great Neck, NY, Neogenix Oncology, Inc., isa research-driven biopharmaceutical company that develops and commercializesinnovative therapeutics and diagnostics for the management of serious anddifficult to treat cancers jeff beck "you know what i mean . Neogenix`s pipeline is derived in part from theHollinshead library of clinically tested vaccines, with the potential to developproducts for a wide range of cancers, including pancreas, colorectal, prostate,lung, ovarian, squamous, and others clapton beck . The company conducts its research anddevelopment work in its laboratories in Great Neck, NY and in Rockville, MD.

Formore information, please visit the company's website at press release may contain, in addition to historical information, certainforward-looking statements that involve risks and uncertainties . Such statementsreflect management`s current views and are based on certain assumptions wired beck . Actualresults could differ materially from those currently anticipated as a result ofa number of factors, including risks and uncertainties yardbirds beck . Neogenix Oncology, Inc.Peter Gordon, CFO, 516-482-1200 Copyright Business Wire 2009 . A thing of beauty is a joy for ever.